MUVON Therapeutics announced that Dr Christine Günther, MD, PhD, has been appointed Chief Technology Officer (CTO), effective December 1, 2025, as the clinical-stage biotech advances its regenerative medicine platform for skeletal muscle tissue repair. The company said her addition will strengthen its leadership team and support the next phase of technology development.
Dr Günther brings over 30 years of experience in cell and gene therapy development, clinical translation, manufacturing and regulatory affairs, combining scientific innovation with operational leadership in the biotech sector. Her professional background includes more than a decade as CEO and Medical Director of Munich-based apceth (now part of Minaris Regenerative Medicine), where she scaled cell therapy programmes and steered the organisation through growth and acquisition. She previously served as Medical Director at the Bavarian Stem Cell and Cord Blood Bank and held leadership roles in European clinical-stage development and cell-manufacturing organisations.
In her new role at MUVON, Dr Günther will oversee the company’s technology strategy, including science, manufacturing and clinical translation, to accelerate its tissue-engineered therapies toward patients. MUVON’s platform focuses on personalised regenerative approaches, with initial programmes such as an autologous muscle precursor cell-based therapy targeting stress urinary incontinence in women.
The appointment aligns with MUVON’s recent clinical progress, including positive Phase 2 results for its lead therapy, and reflects the company’s emphasis on integrating deep expertise in iPSC technology, GMP manufacturing and translational science to advance its innovation pipeline.
